Cimetidine repurposed as a potential immunomodulatory agent against colorectal carcinoma: A systematic review
CONCLUSION: Repurposing of existing drugs like cimetidine has a potential to offer a survival benefit by acting as an immunomodulatory agent in patients undergoing curative resection for CRC. However, the heterogeneity seen in current studies and the evolvement of adjunctive therapies for CRC warrant large-scale, well-designed prospective RCTs to establish the efficacy of cimetidine in CRC.PMID:38592456 | DOI:10.1177/10781552241247007 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Wwm Gunasekara Jlaa Sachindra M T Madhushika Plgc Liyanage S Lekamwasam Source Type: research
Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects
Med Oncol. 2024 Apr 9;41(5):111. doi: 10.1007/s12032-024-02346-0.ABSTRACTThe use of doxorubicin (Dox) in the treatment of breast cancer negatively affects the intestines and other tissues. Many studies have proven that probiotics and vitamin D3 have antitumor and intestinal tissue-protecting properties. To achieve effectiveness and minimize side effects, the current study aims to administer Dox together with probiotics (Lactobacillus acidophilus and Lactobacillus casei) and vitamin D3. Forty-two female BALB/c inbred mice were divided into six groups: Group 1 (Control), Group 2 (Dox), Group 3 (Dox and probiotics), Group 4 (...
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Mohammad Ali Mirzadeh Majid Eslami Ali Ghanbari Sam Zarbakhsh Sedighe Yosefi Abbas Pakdel Source Type: research
Ependymoma from Benign to Highly Aggressive Diseases: A Review
Adv Tech Stand Neurosurg. 2024;50:31-62. doi: 10.1007/978-3-031-53578-9_2.ABSTRACTEpendymomas comprise biologically distinct tumor types with respect to age distribution, (epi)genetics, localization, and prognosis. Multimodal risk-stratification, including histopathological and molecular features, is essential in these biologically defined tumor types. Gross total resection (GTR), achieved with intraoperative monitoring and neuronavigation, and if necessary, second-look surgery, is the most effective treatment. Adjuvant radiation therapy is mandatory in high-risk tumors and in case of residual tumor. There is yet growing e...
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Stephanie T J ünger Valentina Zschernack Martina Messing-J ünger Beate Timmermann Torsten Pietsch Source Type: research
Survivorship concerns among individuals diagnosed with metastatic cancer: Findings from the Cancer Experience Registry
CONCLUSION: Individuals with metastatic cancer experience a variety of moderate-to-severe survivorship concerns that warrant additional investigation.IMPLICATIONS FOR CANCER SURVIVORS: As the population of individuals with metastatic cancer lives longer, future research must investigate solutions to address modifiable factors associated with survivorship concerns, such as unemployment due to disability.PMID:38592607 | DOI:10.1007/s11764-024-01573-8 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Rachelle S Brick Lisa Gallicchio Michelle A Mollica Alexandra K Zaleta Emily S Tonorezos Paul B Jacobsen Kathleen M Castro Melissa F Miller Source Type: research
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial
CONCLUSIONS AND RELEVANCE: These findings suggest that anti-EGFR rechallenge therapy has promising antitumor activity in patients with refractory ctDNA RAS/BRAF wt mCRC. Within the limitation of a subgroup analysis, the absence of liver metastases was associated with significant improved survival.TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02296203; NCT04561336; NCT03227926; NCT05468892.PMID:38592721 | DOI:10.1001/jamanetworkopen.2024.5635 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Davide Ciardiello Erika Martinelli Teresa Troiani Gianluca Mauri Daniele Rossini Giulia Martini Stefania Napolitano Vincenzo Famiglietti Sara Del Tufo Gianluca Masi Daniele Santini Antonio Avallone Filippo Pietrantonio Sara Lonardi Massimo Di Maio Maria G Source Type: research
